Sinotau and Navidea Sign MOU for Beta-Amyloid Imaging Agent
publication date: Oct 30, 2017
Beijing's Sinotau Pharma signed a non-binding MOU with Navidea Biopharma to transfer rights for Navidea's beta-amyloid imaging agent to Cerveau Technologies. Cerveau is a Boston joint venture owned by Sinotau and Canada's Enigma Biomedical. Currently, Sinotau is suing Navidea. It charges Navidea did not transfer the global rights for the beta-amyloid imaging agent, NAV4694, to Sinotau as previously agreed. In 2014, Navidea in-licensed rights to NAV4694 from AstraZeneca, but later decided to emphasize other projects. More details....
Stock Symbols: (NYSE: NAVB) (NYSE: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.